|
|
|
市場調査レポート
最新ドラッグデリバリーシステム：新たな開発動向と新技術
Advanced Drug Delivery Systems: New Developments, New Technologies
| 発行 |
BCC Research |
| 出版日 |
2009年08月 |
商品コード |
96392 |
| ページ情報 |
英文 176 pages |
| 価格 |
|
|
当商品の販売は、2012年04月19日を持ちまして終了しました。
アップデート版はこちらになります。
Advanced Drug Delivery Systems: Technologies and Global Markets
出版日: 2011年10月
商品コード: 219299
Abstract
REPORT HIGHLIGHTS
The global market for advanced drug delivery systems amounted to $134.3
billion in 2008, and was projected to increase to $139 billion in 2009. The
estimate for 2014 is $196.4 billion, for a compound annual growth rate (CAGR)
of 7.2% in the 5-year period. The largest segment of the market is targeted
drug delivery, which reached $50.9 billion in 2009 and is expected to increase
to $80.2 billion in 2014, for a CAGR of 9.5%. Sustained-release products have
the second-largest market share, with estimated sales of $36.1 billion in 2009
and $45.8 billion in 2014, for a CAGR of 4.9%.
INTRODUCTION
STUDY OBJECTIVES
BCC' s goal in conducting this study is to provide an overview of the current
and potential aspects of the global market for advanced drug delivery systems
and its future direction, with an emphasis on newer techniques and products.
The report determines the market size and market leaders, provides a market
overview, and examines factors affecting the markets for drug delivery
systems, including the use of these products in therapeutic markets.
An overview of types of drug delivery systems is also examined along with
sales figures over the 5 year period from 2009 to 2014. This study provides
an overview of the drug delivery market, which BCC projects will grow at a
compound annual growth rate (CAGR) of 7.2% over the forecast period 2009
through 2014.
The study presents market size and future trends, profiles market leaders, and
analyzes factors affecting drug delivery markets and important products. The
report also examines future trends in drug delivery technology, the basic
principles underlying different systems, and their applications. Companies
manufacturing and selling the drug delivery products are also profiled.
Revenues have been broken down by the type of drug delivery systems and by
different regions.
Our key objective is to present a comprehensive analysis of the current market
and the future direction of the advanced drug delivery systems.
REASONS FOR DOING THIS STUDY
The drug delivery market is changing drastically due to the introduction of
new techniques and routes of delivery. R&D spending, along with increasing
competition, patent expiries, new technologies, an international marketplace,
and a changing customer base, is creating a new kind of market for drug
delivery systems. This study looks at almost all the systems affected by
these factors.
This is a very complex market, where many technologies are combined together
to produce a better delivery system, thus creating niche markets with very
specialized applications. The use of liposomes, polymers, etc. in the
sustained-release oral/injectable drug delivery market is a good example.
Prodrugs, PEGylation, nanoparticles, and liposomes are significant new markets.
Acquisition strategies and collaborations by companies are also covered in
this report, for example, the acquisition of the Pulmonary Division of Nektar
Therapeutics by Novartis. This study also discusses the strength and
weaknesses of drug development market in light of the new technologies,
growing competition, and changing customer needs.
INTENDED AUDIENCE
The report consolidates much of the information on new products and new
technologies in the drug delivery industry. The study contributes to
understanding market growth and decline in drug delivery market from the point
of view of the manufacturer and user. This study will be of interest to
manufacturers and end-users in the pharmaceutical and biotechnology
industries, and to companies involved in R&D for drug delivery systems and new
drugs.
SCOPE OF THE STUDY
This study encompasses the major types of drug delivery systems used in the
health industry. BCC analyzes each technology and looks at the manufacturers,
their new products, sales estimates, market projections, and some market share
information. BCC analyzes the industry on a worldwide basis. Patents for drug
delivery technologies are also studied by year, country, and assignee. The
Food and Drug Administration (FDA) approvals for the past 5 years have been
covered. New developments in this field have been examined in detail,
including those that comprise a part of individual company profiles.
METHODOLOGY
Both primary and secondary research methods were used in this report. A
comprehensive search of the literature was conducted. The literature included
technical newsletters and journals as well as many other sources. The data
were collected through interviews and correspondence with various
pharmaceutical/ biotechnical experts. Projections were based on estimates such
as the current number of end users, potential end users, likely unit prices,
rates of consumption, and market trends.
INFORMATION SOURCES
BCC surveyed many companies to obtain data for this study. We gathered the
data from these industries, spoke with officials, and consulted newsletters,
company literature, product literature, a host of technical articles,
journals, indexes, and abstracts. Exhaustive investigations of databases by
key terminology were done. In addition, we compiled data from current
financial and trade information and government sources.
Table of Contents
Chapter- 1: INTRODUCTION -- Complimentary 4
- STUDY OBJECTIVES 1
- REASONS FOR DOING THIS STUDY 1
- INTENDED AUDIENCE 2
- SCOPE OF THE STUDY 2
- METHODOLOGY 2
- INFORMATION SOURCES 2
- ABOUT THE AUTHOR 3
- RELATED BCC REPORTS 3
- BCC ONLINE SERVICES 4
- DISCLAIMER 4
Chapter-2: SUMMARY 2
- SUMMARY 5
- SUMMARY TABLE GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, THROUGH 2014 ($
BILLIONS) 6
- SUMMARY FIGURE GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, 2007-2014 ($
BILLIONS) 6
Chapter-3: OVERVIEW 18
- DEFINITIONS 7
- NEED FOR THE DOSAGE FORMS 7
- CLASSIFICATION OF DOSAGE FORMS ACCORDING TO PHYSICAL PROPERTIES 8
- GASEOUS DOSAGE FORMS 8
- TABLE 1 GASEOUS DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES 9
- LIQUID DOSAGE FORMS 9
- TABLE 2 LIQUID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES 9
- SEMISOLID DOSAGE FORMS 10
- TABLE 3 SEMISOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES 10
- SOLID DOSAGE FORMS 10
- TABLE 4 SOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES 11
- CLASSIFICATION OF DRUG DELIVERY ACCORDING TO ROUTE OF ADMINISTRATION 11
- TOPICAL DRUG DELIVERY 12
- TABLE 5 TOPICAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 12
- ORAL DRUG DELIVERY 13
- TABLE 6 ORAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 13
- INJECTABLE OR PARENTERAL DRUG DELIVERY 13
- TABLE 7 INJECTABLE OR PARENTERAL DRUG DELIVERY, ADVANTAGES AND
DISADVANTAGES 14
- RECTAL DRUG DELIVERY 14
- TABLE 8 RECTAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 15
- NASAL DRUG DELIVERY 15
- TABLE 9 NASAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 15
- TABLE 9 (CONTINUED) 16
- VAGINAL DRUG DELIVERY 16
- TABLE 10 VAGINAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 16
- OCULAR DRUG DELIVERY 17
- TABLE 11 OCULAR DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 17
- PULMONARY DRUG DELIVERY 17
- TABLE 12 PULMONARY DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 18
- CLASSIFICATION OF DRUG DELIVERY BASED ON TECHNOLOGY 18
- SUSTAINED-RELEASE DRUG DELIVERY 18
- TABLE 13 SUSTAINED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES 19
- DELAYED-RELEASE DRUG DELIVERY 19
- TABLE 14 DELAYED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES 19
- PRODRUGS 20
- TABLE 15 PRODRUGS, ADVANTAGES AND DISADVANTAGES 20
- IMPLANTS AND IUDS 20
- TABLE 16 IMPLANTS AND IUDS, ADVANTAGES AND DISADVANTAGES 21
- TARGETED DRUG DELIVERY 21
- Nanoparticles 21
- Liposomes 22
- TABLE 17 LIPOSOMES, ADVANTAGES AND DISADVANTAGES 22
- Polymers 22
- TABLE 18 POLYMERS, ADVANTAGES AND DISADVANTAGES 23
- Monoclonal Antibodies 23
- TABLE 19 MONOCLONAL ANTIBODIES, ADVANTAGES AND DISADVANTAGES 24
- PEGylation 24
- TABLE 20 PEGYLATION, ADVANTAGES AND DISADVANTAGES 24
Chapter-4: REGULATORY ISSUES 7
- TABLE 21 FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMS (2005 TO FEB 2009) 25
- TABLE 21 (CONTINUED) 26
- TABLE 21 (CONTINUED) 27
- TABLE 22 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR,
2005- FEB. 2009 28
- FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR,
2005 TO FEB. 2009 28
- TABLE 23 APPROVED DRUGS OF VARIOUS DOSAGE FORMS, THROUGH OTHER AGENCIES
(2005 TO FEB 2009) 29
- TABLE 24 RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY SYSTEMS (2005 TO FEB.
2009) 29
- TABLE 24 (CONTINUED) 30
- REGULATORY ISSUES (CONTINUED) 31
Chapter-5: CLASSIFICATION OF DRUG PRODUCTS BASED ON DRUG DELIVERY TYPE 14
- SUSTAINED-RELEASE ORAL DOSAGE FORMS 32
- TABLE 25 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE ORAL
DOSAGE FORMS 32
- TABLE 25 (CONTINUED) 33
- SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS 34
- TABLE 26 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE INJECTABLE
DOSAGE FORMS 34
- SUSTAINED-RELEASE TOPICAL DOSAGE FORMS 35
- TABLE 27 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE TOPICAL
DOSAGE FORMS 35
- PRODRUGS 35
- TABLE 28 MAJOR SUPPLIERS AND MANUFACTURERS OF PRODRUGS 35
- TABLE 28 (CONTINUED) 36
- IMPLANTS AND IUDS 36
- TABLE 29 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS 36
- TRANSDERMAL DRUG DELIVERY SYSTEMS 36
- TABLE 30 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY
SYSTEMS 36
- TABLE 30 (CONTINUED) 37
- LIPOSOMES 38
- TABLE 31 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES 38
- NANOPARTICLES 38
- TABLE 32 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES 38
- POLYMERS 39
- TABLE 33 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS 39
- MONOCLONAL ANTIBODIES 40
- TABLE 34 MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES 40
- PEGYNOLOGY 41
- TABLE 35 MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY 41
- BUCCAL DRUG DELIVERY SYSTEMS 41
- TABLE 36 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DRUG DELIVERY SYSTEMS
41
- RECTAL DRUG DELIVERY SYSTEMS 42
- TABLE 37 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DRUG DELIVERY SYSTEMS
42
- VAGINAL DRUG DELIVERY SYSTEMS 42
- TABLE 38 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DRUG DELIVERY
SYSTEMS 42
- TABLE 7 (CONTINUED) 43
- OCULAR DRUG DELIVERY SYSTEMS 43
- TABLE 39 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DRUG DELIVERY SYSTEMS
43
- TABLE 39 (CONTINUED) 44
- INHALATION SYSTEMS 44
- TABLE 40 MAJOR SUPPLIERS AND MANUFACTURERS OF INHALTION SYSTEMS 44
- TABLE 40 (CONTINUED) 45
Chapter-6: INDUSTRY STRUCTURE 18
- SUSTAINED-RELEASE DOSAGE FORMS 46
- SUSTAINED-RELEASE ORAL DOSAGE FORM 46
- TABLE 41 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE ORAL
DOSAGE FORMS, 2008 (%) 46
- FIGURE 2 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE ORAL
DOSAGE FORMS, 2008 (%) 47
- SUSTAINED-RELEASE INJECTABLE DOSAGE FORM 48
- TABLE 42 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE
INJECTABLE DOSAGE FORMS, 2008 (%) 48
- FIGURE 3 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE INJECTABLE
DOSAGE FORMS, 2008 (%) 48
- SUSTAINED-RELEASE TOPICAL DOSAGE FORM 49
- TABLE 43 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE TOPICAL
DOSAGE FORMS, 2008 (%) 49
- FIGURE 4 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE TOPICAL
DOSAGE FORMS, 2008 (%) 49
- PRODRUGS 50
- TABLE 44 SHARES OF MANUFACTURERS/SUPPLIERS FOR PRODRUGS, 2008 (%) 50
- FIGURE 5 SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS, 2008 (%) 50
- IMPLANTS AND IUDS 51
- TABLE 45 SHARES OF MANUFACTURERS FOR IMPLANTS AND IUDS, 2008 (%) 51
- FIGURE 6 SHARES OF MANUFACTURERS OF IMPLANTS AND IUDS, 2008 (%) 51
- TRANSDERMAL DRUG DELIVERY SYSTEMS 52
- TABLE 46 SHARES OF MANUFACTURERS/SUPPLIERS FOR TRANSDERMAL DRUG DELIVERY
SYSTEMS, 2008 (%) 52
- FIGURE 7 SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY
SYSTEMS, 2008 (%) 52
- TARGETED DRUG DELIVERY SYSTEMS 53
- LIPOSOMES 53
- TABLE 47 SHARES OF MANUFACTURERS/SUPPLIERS FOR LIPOSOMES, 2008 (%) 53
- FIGURE 8 SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES, 2008 (%) 53
- NANOPARTICLES 54
- TABLE 48 SHARES OF MANUFACTURERS/SUPPLIERS FOR NANOPARTICLES, 2008 (%) 54
- FIGURE 9 SHARES OF MANUFACTURERS/SUPPLIERS OF NANOPARTICLES, 2008 (%) 54
- POLYMERS 55
- TABLE 49 SHARES OF MANUFACTURERS/SUPPLIERS FOR POLYMERS, 2008 (%) 55
- FIGURE 10 SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS, 2008 (%) 55
- MONOCLONAL ANTIBODIES 56
- TABLE 50 SHARES OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2008
(%) 56
- FIGURE 11 SHARES OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2008
(%) 56
- PEGNOLOGY 57
- TABLE 51 SHARES OF MANUFACTURERS/SUPPLIERS FOR PEGNOLOGY, 2008 (%) 57
- FIGURE 12 SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY, 2008 (%) 57
- TRANSMUCOSAL DRUG DELIVERY SYSTEMS 58
- BUCCAL DRUG DELIVERY SYSTEMS 58
- TABLE 52 SHARES OF MANUFACTURERS/SUPPLIERS FOR BUCCAL DRUG DELIVERY
SYSTEMS, 2008 (%) 58
- FIGURE 13 SHARES OF MANUFACTURERS/ SUPPLIERS OF BUCCAL DRUG DELIVERY
SYSTEMS, 2008 (%) 58
- RECTAL DRUG DELIVERY SYSTEMS 59
- TABLE 53 SHARES OF MANUFACTURERS/SUPPLIERS FOR RECTAL DRUG DELIVERY
SYSTEMS, 2008 (%) 59
- FIGURE 14 SHARES OF MANUFACTURERS/ SUPPLIERS OF RECTAL DRUG DELIVERY
SYSTEMS, 2008 (%) 59
- VAGINAL DRUG DELIVERY SYSTEMS 60
- TABLE 54 SHARES OF MANUFACTURERS/SUPPLIERS FOR VAGINAL DRUG DELIVERY
SYSTEMS, 2008 (%) 60
- FIGURE 15 SHARES OF MANUFACTURERS/ SUPPLIERS OF VAGINAL DRUG DELIVERY
SYSTEMS, 2008 (%) 60
- OCULAR DRUG DELIVERY SYSTEMS 61
- TABLE 55 SHARES OF MANUFACTURERS/SUPPLIERS FOR OCULAR DRUG DELIVERY
SYSTEMS, 2008 (%) 61
- FIGURE 16 SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR DRUG DELIVERY
SYSTEMS, 2008 (%) 61
- INHALATION SYSTEMS 62
- TABLE 56 SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008 (%)
62
- FIGURE 17 SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008
(%) 62
- Inhalation Systems (Continued) 63
Chapter-7: DEMAND AND USE 4
- TABLE 59 GLOBAL SALES OF DRUG DELIVERY PRODUCTS, THROUGH 2014 ($ BILLIONS)
68
- FIGURE 18 GLOBAL SALES OF DRUG DELIVERY SYSTEMS, 2007-2014 ($ BILLIONS) 69
- TABLE 60 MARKET SHARE OF DRUG DELIVERY PRODUCTS, 2008 (%) 69
- FIGURE 19 MARKET SHARE OF DRUG DELIVERY SYSTEM, 2008 (%) 70
- SUSTAINED-RELEASE ORAL DOSAGE FORMS 70
- MARKET SIZE 71
- TABLE 61 GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, THROUGH 2014
($ MILLIONS) 71
- FIGURE 20 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS,
2007-2014 ($ MILLIONS) 72
- MARKET OVERVIEW 72
- SUSTAINED-RELEASE INJECTABLE DOSGAE FORM 73
- MARKET SIZE 74
- TABLE 62 GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS,
THROUGH 2014 ($ MILLIONS) 74
- FIGURE 21 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS,
2007-2014 ($ MILLIONS) 75
- MARKET OVERVIEW 75
- SUSTAINED-RELEASE TOPICAL DOSAGE FORMS 76
- MARKET SIZE 76
- TABLE 63 GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, THROUGH
2014 ($ MILLIONS) 76
- FIGURE 22 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS,
2007-2014 ($ MILLIONS) 77
- MARKET OVERVIEW 77
- PRODRUGS 78
- MARKET SIZE 78
- TABLE 64 TOTAL GLOBAL SALES OF PRODRUGS, THROUGH 2014 ($ MILLIONS) 79
- FIGURE 23 GLOBAL SALES OF PRODRUGS, 2007-2014 ($ MILLIONS) 79
- MARKET OVERVIEW 79
- IMPLANTS AND IUDS 80
- MARKET SIZE 80
- TABLE 65 GLOBAL SALES OF IMPLANTS AND IUDS, THROUGH 2014 ($ MILLIONS) 81
- FIGURE 24 TOTAL GLOBAL SALES OF IMPLANTS AND IUDS, 2007-2014 ($ MILLIONS)
81
- MARKET OVERVIEW 81
- TRANSDERMAL DRUG DELIVERY 82
- MARKET SIZE 82
- TABLE 66 GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2014
($ MILLIONS) 83
- FIGURE 25 TOTAL GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS,
2007-2014 ($ MILLIONS) 83
- MARKET OVERVIEW 83
- LIPOSOMES DRUG DELIVERY 84
- MARKET SIZE 84
- TABLE 67 GLOBAL SALES OF LIPOSOMES, THROUGH 2014 ($ MILLIONS) 85
- FIGURE 26 TOTAL GLOBAL SALES OF LIPOSOMES, 2007-2014 ($ MILLIONS) 85
- MARKET OVERVIEW 85
- NANOPARTICLES 86
- MARKET SIZE 86
- TABLE 68 GLOBAL SALES OF NANOPARTICLES, THROUGH 2014 ($ MILLIONS) 87
- FIGURE 27 GLOBAL SALES OF NANOPARTICLES, 2007-2014 ($ MILLIONS) 87
- MARKET OVERVIEW 87
- POLYMERS 88
- MARKET SIZE 88
- TABLE 69 GLOBAL SALES OF POLYMERS, THROUGH 2014 ($ MILLIONS) 88
- FIGURE 28 GLOBAL SALES OF POLYMERS, 2007-2014 ($ MILLIONS) 89
- MARKET OVERVIEW 89
- PEGYLATED DRUG DELIVERY 90
- MARKET SIZE 90
- TABLE 70 GLOBAL SALES OF PEGYLATED DRUG DELIVERY, THROUGH 2014 ($
MILLIONS) 90
- FIGURE 29 TOTAL GLOBAL SALES OF PEGYLATED DRUG DELIVERY, 2007-2014 ($
MILLIONS) 91
- MARKET OVERVIEW 91
- MONOCLONAL ANTIBODIES 92
- MARKET SIZE 92
- TABLE 71 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2014 ($ MILLIONS)
92
- FIGURE 30 TOTAL GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2007-2014 ($
MILLIONS) 93
- MARKET OVERVIEW 93
- BUCCAL DRUG DELIVERY 94
- MARKET SIZE 94
- TABLE 72 GLOBAL SALES OF BUCCAL DRUG DELIVERY, THOUGH 2014 ($ MILLIONS) 94
- FIGURE 31 TOTAL GLOBAL SALES OF BUCCAL DRUG DELIVERY, 2007-2014 ($
MILLIONS) 95
- MARKET OVERVIEW 95
- RECTAL DRUG DELIVERY 96
- MARKET SIZE 96
- TABLE 73 GLOBAL SALES OF RECTAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS) 96
- FIGURE 32 TOTAL GLOBAL SALES OF RECTAL DRUG DELIVERY, 2007-2014 ($
MILLIONS) 97
- MARKET OVERVIEW 97
- OCULAR DRUG DELIVERY 97
- MARKET SIZE 98
- TABLE 74 GLOBAL SALES OF OCULAR DRUG DELIVERY, THROUGH 2014 ($ MILLIONS) 98
- FIGURE 33 TOTAL GLOBAL SALES OF OCULAR DRUG DELIVERY, 2007-2014 ($
MILLIONS) 98
- MARKET OVERVIEW 99
- VAGINAL DRUG DELIVERY 99
- MARKET SIZE 99
- TABLE 75 GLOBAL SALES OF VAGINAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)
100
- FIGURE 34 TOTAL GLOBAL SALES OF VAGINAL DRUG DELIVERY, 2007-2014 ($
MILLIONS) 100
- MARKET OVERVIEW 100
- INHALATION DRUG DELIVERY 101
- MARKET SIZE 101
- TABLE 76 GLOBAL SALES OF INHALATION DRUG DELIVERY, THROUGH 2014 ($
MILLIONS) 101
- FIGURE 35 TOTAL GLOBAL SALES OF INHALATION DRUG DELIVERY, 2007-2014 ($
MILLIONS) 102
- MARKET OVERVIEW 102
- Market Overview (Continued) 103
Chapter-8: MARKET ANALYSIS 36
Chapter-9: NEW DEVELOPMENTS 13
- TABLE 77 DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE FORMS 104
- TABLE 77 (CONTINUED) 105
- TABLE 78 DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS 105
- TABLE 78 (CONTINUED) 106
- TABLE 79 DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL DOSAGE FORMS 106
- TABLE 80 DEVELOPMENTS IN PRODRUGS 106
- TABLE 80 (CONTINUED) 107
- TABLE 81 DEVELOPMENTS IN IMPLANTS AND IUDS 107
- TABLE 81 (CONTINUED) 108
- TABLE 82 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS 108
- TABLE 82 (CONTINUED) 109
- TABLE 83 DEVELOPMENTS IN LIPOSOMAL DELIVERY 109
- TABLE 83 (CONTINUED) 110
- TABLE 84 DEVELOPMENTS IN PEGYLATED DRUG DELIVERY 110
- TABLE 84 (CONTINUED) 111
- TABLE 85 DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY 112
- TABLE 86 DEVELOPMENTS IN MONOCLONAL ANTIBODIES 112
- TABLE 86 (CONTINUED) 113
- TABLE 87 DEVELOPMENTS IN BUCCAL DRUG DELIVERY 114
- TABLE 88 DEVELOPMENTS IN VAGINAL DRUG DELIVERY 114
- TABLE 89 DEVELOPMENTS IN RECTAL DRUG DELIVERY 115
- TABLE 90 DEVELOPMENTS IN INHALATION DRUG DELIVERY 115
- TABLE 90 (CONTINUED) 116
Chapter-10: MARKET BY THERAPEUTIC AREAS 19
- MARKET SIZE 117
- TABLE 91 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN EACH THERAPEUTIC AREA,
THROUGH 2014 ($ BILLIONS) 117
- TABLE 91 (CONTINUED) 118
- FIGURE 36 GLOBAL SALES OF DRUGS TO TREAT LIVER DISEASES, 2007-014 ($
BILLIONS) 118
- MARKET SHARE 119
- TABLE 92 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%) 119
- FIGURE 37 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%) 119
- CARDIOVASCULAR DISEASES 120
- MARKET SIZE 120
- TABLE 93 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES,
THROUGH 2004 ($ BILLIONS) 120
- FIGURE 38 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR
DISEASES, 2007-2014 ($ BILLIONS) 121
- ONCOLOGY 121
- MARKET SIZE 121
- TABLE 94 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, THROUGH 2014
($ BILLIONS) 122
- FIGURE 39 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, 2007-2014 ($
BILLIONS) 122
- GASTROINTESTINAL 122
- MARKET SIZE 122
- TABLE 95 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL
DISORDERS, THROUGH 2014 ($ BILLIONS) 123
- FIGURE 40 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL
DISORDERS, 2007-2014 ($ BILLIONS) 123
- UROLOGY 123
- MARKET SIZE 124
- TABLE 96 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, THROUGH 2014 ($
BILLIONS) 124
- FIGURE 41 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, 2007-2014 ($
BILLIONS) 124
- DIABETES 125
- MARKET SIZE 125
- TABLE 97 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, THROUGH
2014 ($ BILLIONS) 125
- FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET,
2007-2014 ($ BILLIONS) 126
- CENTRAL NERVOUS SYSTEM DISORDER 126
- MARKET SIZE 126
- TABLE 98 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTERAL NERVOUS SYSTEM
MARKET, THROUGH 2014 ($ BILLIONS) 127
- FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTRAL NERVOUS SYSTEM
MARKET, 2007-2014 ($ BILLIONS) 127
- RESPIRATORY DRUG DELIVERY SYSTEMS 127
- MARKET SIZE 128
- TABLE 99 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RESPIRATORY DISEASES,
THROUGH 2014 ($ BILLIONS) 128
- FIGURE 44 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RISPIRATORY DISEASES,
2007-2014 ($ BILLIONS) 128
- INFLAMMATORY DISEASES AND ALLERGY 128
- MARKET SIZE 129
- TABLE 100 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND
ALLERGY, 2007-2014 ($ BILLIONS) 129
- FIGURE 45 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND
ALLERGY DISEASES, 2007-2014 ($ BILLIONS) 129
- OPHTHALMOLOGY 130
- MARKET SIZE 130
- TABLE 101 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH
2014 ($ BILLIONS) 130
- FIGURE 46 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,
2007-2014 ($ BILLIONS) 131
- VIRAL AND BACTERIAL DISEASES 131
- MARKET SIZE 131
- TABLE 102 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL
DISEASES, THROUGH 2014 ($ BILLIONS) 132
- FIGURE 47 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL
DISEASES, 2007-2014 ($ BILLIONS) 132
- HORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGY 132
- MARKET SIZE 133
- TABLE 103 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT
THERAPY AND GYNECOLOGY, THROUGH 2014 ($ BILLIONS) 133
- FIGURE 48 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT
THERAPY AND GYNECOLOGY, 2007-2014 ($ BILLIONS) 133
- OTHERS 134
- MARKET SIZE 134
- TABLE 104 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS
AND TECHNOLOGIES, THROUGH 2014 ($ BILLIONS) 134
- FIGURE 49 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS
AND TECHNOLOGIES, 2007-2014 ($ BILLIONS) 135
Chapter-11: PATENT ANALYSIS 11
- PATENTS BY YEAR 136
- TABLE 105 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2009 137
- FIGURE 50 NUMBER OF PATENTS, 2005-2009 137
- PATENTS BY TYPE 137
- TABLE 106 NUMBER OF PATENTS BY TYPE, 2005-2009 138
- FIGURE 51 NUMBER OF PATENTS BY TYPE, 2005-2009 138
- FIGURE 52 TOTAL NUMBER OF PATENTS, SHARE BY TYPE, 2005-2009 (%) 139
- PATENTS BY COUNTRY 139
- TABLE 107 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009 140
- FIGURE 53 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009 141
- PATENTS BY COMPANY 141
- TABLE 108 NUMBER OF PATENTS BY COMPANY, 2005-2009 142
- TABLE 108 (CONTINUED) 143
- TABLE 108 (CONTINUED) 144
- FIGURE 54 NUMBER OF PATENTS BY COMPANY, 2005-2009 145
- PATENTS BY ASSIGNEE 145
- TABLE 109 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009 145
- FIGURE 55 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009 146
Chapter-12: COMPANY PROFILES 30
- ABBOTT LABORATORIES 147
- ABRAXIS BIOSCIENCE, INC. 147
- AKELA PHARMA 148
- AKORN, INC. 148
- ALCON, INC. 149
- ALEXION PHARMACEUTICALS 149
- ALKERMES, INC. 150
- ALLERGAN 150
- ALPHARX 151
- AMGEN 151
- ANTIGENICS 151
- A P PHARMA 152
- ASTELLAS PHARMA 152
- ASTRAZENECA 153
- ATON PHARMA 153
- BARR PHARMACEUTICALS, INC. 153
- BAXTER 154
- BAYER HEALTHCARE 154
- BIOGEN IDEC 155
- BIOSANTE PHARMACEUTICALS, INC. 155
- BIOVAIL 155
- BOEHRINGER INGELHEIM 156
- BRISTOL MYERS SQUIBB 156
- CENTOCOR 157
- CEPHALON INC. 157
- COLUMBIA LABS 157
- DIATOS SA 158
- EISAI CO. 158
- ELAN 159
- ENZON 159
- EURAND N.V. 159
- GENENTECH 160
- GENEREX BIOTECH 160
- GENZYME 161
- GILEAD SCIENCES, INC. 161
- GLAXOSMITHKLINE PLC 161
- IMCLONE SYSTEMS 162
- JOHNSON AND JOHNSON 162
- KING PHARMACEUTICALS 163
- K.V. PHARMACEUTICAL CO. 164
- LAVIPHARM CORPORATION 164
- 3M COMPANY 165
- MERCK & CO. 165
- MYLAN LABORATORIES, INC. 166
- NEKTAR THERAPEUTICS 166
- NOVEN PHARMACEUTICALS, INC. 167
- NOVARTIS AG 168
- NOVAVAX, INC. 168
- NYCOMED US, INC. 169
- OSI PHARMACEUTICALS, INC. 169
- PAR PHARMACEUTICAL COMPANIES, INC. 170
- PDL BIOPHARMA, INC. 170
- PFIZER INC. 170
- QLT, INC. 171
- ROCHE 171
- SANOFI-AVENTIS 172
- SCHERING-PLOUGH 172
- TEVA PHARMACEUTICAL INDUSTRIES, LTD. 173
- WATSON PHARMACEUTICALS, INC. 173
- WYETH, INC. 174
APPENDIX: ABBREVIATIONS 175
- ABBREVIATIONS 175
- APPENDIX (CONTINUED) 176
|
 |
